LINC00861 inhibits the progression of cervical cancer&nbsp;cells by functioning as a ceRNA for miR‑513b‑5p and&nbsp;regulating the PTEN/AKT/mTOR signaling pathway

Liu,Hui; Zhang,Ling; Ding,Xiaoling; Sui,Xuezuo

doi:10.3892/mmr.2020.11662

LINC00861 inhibits the progression of cervical cancer cells by functioning as a ceRNA for miR‑513b‑5p and regulating the PTEN/AKT/mTOR signaling pathway

Authors:
- Hui Liu
- Ling Zhang
- Xiaoling Ding
- Xuezuo Sui
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong 264013, P.R. China, Department of Gynaecology and Obstetrics, Yidu Central Hospital of Weifang, Qingzhou, Shandong 262500, P.R. China, Department of Gynaecology and Obstetrics, Maternal and Child Health Hospital of Qingzhou, Qingzhou, Shandong 264000, P.R. China
Published online on: November 3, 2020 https://doi.org/10.3892/mmr.2020.11662
Article Number: 24
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) have been discovered to serve important roles in a variety of types of cancer, including cervical cancer. The low expression of lncRNA long intergenic non‑protein coding RNA 861 (LINC00861) is related to poor prognosis in ovarian cancer. However, the effects and underlying mechanisms of LINC00861 in cervical cancer remain largely unknown. The present study aimed to examine the role of LINC00861 in the development and progression of ovarian cancer and its underlying mechanisms. The expression levels of LINC00861 and microRNA (miR)‑513b‑5p were analyzed using reverse transcription‑quantitative PCR analysis. Cell proliferation, migration and invasion were measured by using Cell Counting Kit‑8, colony formation, wound healing and Transwell assays, respectively. A luciferase assay was used to determine whether miR‑513b‑5p targeted LINC00861 and PTEN. The expression of protein was measured by using western blot assay. The results of the present study discovered that LINC00861 expression levels were significantly downregulated in cervical cancer tissues and CaSki and ME‑180 cell lines. Downregulated LINC00861 expression levels were identified to be associated with an advanced‑stage, lymph node metastasis and the poor survival of patients with cervical cancer. Gene Set Enrichment Analysis revealed that the PI3K/AKT/mTOR signaling pathway was significantly enriched in cervical tumors expressing low expression levels of LINC00861 compared with tumors expressing high levels of LINC00861. The overexpression of LINC00861 reduced cervical cancer cell proliferation, migration, invasion and epithelial‑mesenchymal transition (EMT) processes, upregulated PTEN protein expression levels and downregulated phosphorylated (p)‑AKT and p‑mTOR protein expression levels. The regulatory relationship between LINC00861, microRNA (miR)‑513b‑5p and PTEN was validated using a dual luciferase reporter gene assay. PTEN expression levels were significantly downregulated in the miR‑513b‑5p mimic group and significantly upregulated in the miR‑513b‑5p inhibitor group compared with the mimic NC and inhibitor NC in both cell lines. Furthermore, LINC00861 was suggested to serve as a competing endogenous RNA by sponging miR‑513b‑5p and consequently upregulating the expression levels of PTEN in cervical cancer cells. The expression of PTEN, the phosphorylation of Akt and mTOR and and the EMT phenotype were rescued following co‑transfection with LINC00861 and miR‑513b‑5p mimics. In conclusion, the findings of the present study indicated that the LINC00861/miR‑513b‑5p axis may inhibit the progression of cervical cancer cells through the PTEN/AKT/mTOR signaling pathway to suppress the EMT process.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Cohen PA, Jhingran A, Oaknin A and Denny L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
3	Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI
4	Nagano T and Fraser P: No-nonsense functions for long noncoding RNAs. Cell. 145:178–181. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hu YW, Kang CM, Zhao JJ, Nie Y, Zheng L, Li HX, Li X, Wang Q and Qiu YR: LncRNA PLAC2 down-regulates RPL36 expression and blocks cell cycle progression in glioma through a mechanism involving STAT1. J Cell Mol Med. 22:497–510. 2018. View Article : Google Scholar : PubMed/NCBI
6	Yang L, Li Y, Gong R, Gao M, Feng C, Liu T, Sun Y, Jin M, Wang D, Yuan Y, et al: The long non-coding RNA-ORLNC1 regulates bone mass by directing mesenchymal stem cell fate. Mol Ther. 27:394–410. 2019. View Article : Google Scholar : PubMed/NCBI
7	Hu X, Goswami S, Qiu J, Chen Q, Laverdure S, Sherman BT and Imamichi T: Profiles of long non-coding RNAs and mRNA expression in human macrophages regulated by interleukin-27. Int J Mol Sci. 20:62072019. View Article : Google Scholar
8	Wang M, Zhou L, Yu F, Zhang Y, Li P and Wang K: The functional roles of exosomal long non-coding RNAs in cancer. Cell Mol Life Sci. 76:2059–2076. 2019. View Article : Google Scholar : PubMed/NCBI
9	Zhang F, Zhang L and Zhang C: Long noncoding RNAs and tumorigenesis: Genetic associations, molecular mechanisms, and therapeutic strategies. Tumour Biol. 37:163–175. 2016. View Article : Google Scholar : PubMed/NCBI
10	Zheng M, Hu Y, Gou R, Nie X, Li X, Liu J and Lin B: Identification three LncRNA prognostic signature of ovarian cancer based on genome-wide copy number variation. Biomed Pharmacother. 124:1098102020. View Article : Google Scholar : PubMed/NCBI
11	Lv Y, Wei W, Huang Z, Chen Z, Fang Y, Pan L, Han X and Xu Z: Long non-coding RNA expression profile can predict early recurrence in hepatocellular carcinoma after curative resection. Hepatol Res. 48:1140–1148. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Li Y, Wang Q, Zhang X, Wang D, Tang HC, Meng X and Ding X: Identification of an lncRNAmiRNAmRNA interaction mechanism in breast cancer based on bioinformatic analysis. Mol Med Rep. 16:5113–5120. 2017. View Article : Google Scholar : PubMed/NCBI
13	Shen CJ, Cheng YM and Wang CL: LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target. 25:637–644. 2017. View Article : Google Scholar : PubMed/NCBI
14	Li R, Liu J and Qi J: Knockdown of long non-coding RNA CCAT1 suppresses proliferation and EMT of human cervical cancer cell lines by down-regulating Runx2. Exp Mol Pathol. 113:1043802020. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
17	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
18	Hu R and Lu Z: Long non-coding RNA HCP5 promotes prostate cancer cell proliferation by acting as the sponge of miR-4656 to modulate CEMIP expression. Oncol Rep. 43:328–336. 2020.PubMed/NCBI
19	Bai J, Xu J, Zhao J and Zhang R: LncRNA NBR2 suppresses migration and invasion of colorectal cancer cells by downregulating miRNA-21. Hum Cell. 33:98–103. 2020. View Article : Google Scholar : PubMed/NCBI
20	Liang H, Zhang C, Guan H, Liu J and Cui Y: LncRNA DANCR promotes cervical cancer progression by upregulating ROCK1 via sponging miR-335-5p. J Cell Physiol. 234:7266–7278. 2019. View Article : Google Scholar : PubMed/NCBI
21	Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F and Ochiya T: Emerging roles of long non-coding RNA in cancer. Cancer Sci. 109:2093–2100. 2018. View Article : Google Scholar : PubMed/NCBI
22	Dong P, Xiong Y, Yue J, Xu D, Ihira K, Konno Y, Kobayashi N, Todo Y and Watari H: Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes. J Exp Clin Cancer Res. 38:2952019. View Article : Google Scholar : PubMed/NCBI
23	Zhang J, Li Z, Liu L, Wang Q, Li S, Chen D, Hu Z, Yu T, Ding J, Li J, et al: Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway. Hepatology. 67:171–187. 2018. View Article : Google Scholar : PubMed/NCBI
24	Ghafouri-Fard S and Taheri M: Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA. Biomed Pharmacother. 118:1091292019. View Article : Google Scholar : PubMed/NCBI
25	Yao Y, Zhang T, Qi L, Zhou C, Wei J, Feng F, Liu R and Sun C: Integrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancer. J Cell Mol Med. 23:8410–8419. 2019. View Article : Google Scholar : PubMed/NCBI
26	Chen X, Chen Z, Yu S, Nie F, Yan S, Ma P, Chen Q, Wei C, Fu H, Xu T, et al: Long noncoding RNA LINC01234 functions as a competing endogenous RNA to regulate CBFB expression by sponging miR-204-5p in gastric cancer. Clin Cancer Res. 24:2002–2014. 2018. View Article : Google Scholar : PubMed/NCBI
27	Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H, Kong J, Ding K, Shen HM, Wu H, et al: Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Mol Cancer. 16:1182017. View Article : Google Scholar : PubMed/NCBI
28	Qiu BQ, Lin XH, Ye XD, Huang W, Pei X, Xiong D, Long X, Zhu SQ, Lu F, Lin K, et al: Long non-coding RNA PSMA3-AS1 promotes malignant phenotypes of esophageal cancer by modulating the miR-101/EZH2 axis as a ceRNA. Aging. 12:1843–1856. 2020. View Article : Google Scholar : PubMed/NCBI
29	Lin W, Ye H, You K and Chen L: Up-regulation of circ_LARP4 suppresses cell proliferation and migration in ovarian cancer by regulating miR-513b-5p/LARP4 axis. Cancer Cell Int. 20:52020. View Article : Google Scholar : PubMed/NCBI
30	Wang X, Zhang X, Wang G, Wang L, Lin Y and Sun F: Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells. Gene. 626:344–353. 2017. View Article : Google Scholar : PubMed/NCBI
31	Yao H, Kong F and Zhou Y: MiR-182 promotes cell proliferation, migration and invasion by targeting FoxF2 in endometrial carcinoma cells. Int J Clin Exp Pathol. 12:1248–1259. 2019.PubMed/NCBI
32	Lv Y, Ye D, Qiu S, Zhang J, Shen Z, Shen Y and Deng H: MiR-182 regulates cell proliferation and apoptosis in laryngeal squamous cell carcinoma by targeting the CRR9. Biosci Rep. 39:BSR201913482019. View Article : Google Scholar : PubMed/NCBI
33	Ngeow J, Sesock K and Eng C: Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat. 165:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
34	Patel R, Brzezinska EA, Repiscak P, Ahmad I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G, et al: Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer. Cancer Res. 80:576–590. 2020. View Article : Google Scholar : PubMed/NCBI
35	Kaur G, Balasubramaniam SD and Lee YJ: IGFBP-2 in cervical cancer development. Exp Mol Pathol. 113:212020. View Article : Google Scholar
36	Li A, Qiu M, Zhou H, Wang T and Guo W: PTEN, insulin resistance and cancer. Curr Pharm Des. 23:3667–3676. 2017. View Article : Google Scholar : PubMed/NCBI
37	Shao S, Wang C, Wang S, Zhang H and Zhang Y: LncRNA STXBP5-AS1 suppressed cervical cancer progression via targeting miR-96-5p/PTEN axis. Biomed Pharmacother. 117:152019. View Article : Google Scholar
38	Wang S, Jiang W, Zhang X, Lu Z, Geng Q, Wang W, Li N and Cai X: LINC-PINT alleviates lung cancer progression via sponging miR-543 and inducing PTEN. Cancer Med. 9:1999–2009. 2020. View Article : Google Scholar : PubMed/NCBI
39	Shi YP, Liu GL, Li S and Liu XL: miR-17-5p knockdown inhibits proliferation, autophagy and promotes apoptosis in thyroid cancer via targeting PTEN. Neoplasma. 67:249–258. 2020. View Article : Google Scholar : PubMed/NCBI
40	Fu BM: Tumor metastasis in the microcirculation. Adv Exp Med Biol. 1097:201–218. 2018. View Article : Google Scholar : PubMed/NCBI
41	Ombrato L and Malanchi I: The EMT universe: Space between cancer cell dissemination and metastasis initiation. Crit Rev Oncog. 19:349–361. 2014. View Article : Google Scholar : PubMed/NCBI
42	Odero-Marah V, Hawsawi O, Henderson V and Sweeney J: Epithelial-mesenchymal transition (EMT) and prostate cancer. Adv Exp Med Biol. 1095:101–110. 2018. View Article : Google Scholar : PubMed/NCBI
43	Liang H, Yu T, Han Y, Jiang H, Wang C, You T, Zhao X, Shan H, Yang R, Yang L, et al: LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 17:1192018. View Article : Google Scholar : PubMed/NCBI
44	Li ZT, Zhang X, Wang DW, Xu J, Kou KJ, Wang ZW, Yong G, Liang DS and Sun XY: Overexpressed lncRNA GATA6-AS1 inhibits LNM and EMT via FZD4 through the Wnt/β-catenin signaling pathway in GC. Mol Ther Nucleic Acids. 19:827–840. 2019. View Article : Google Scholar : PubMed/NCBI